Cargando…

The efficacy of Yiqi Huoxue method in treating coronary artery disease after percutaneous coronary intervention: A meta-analysis in accordance with PRISMA guideline

Percutaneous coronary intervention (PCI), the most common method in treating coronary artery disease (CAD), has a variety of side effects. Yiqi Huoxue therapy (YQHX) can effectively alleviate the symptoms of patients and reduce the side effects. However, a reliable and systematic assessment of the m...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Miao, Sun, Ming-Yue, Chen, Qi-Ting, Xu, Feng-Qin, Chen, Zong-Zheng, Wei, Wen-Bo, Wang, Rui-Ting, Xu, Gui-Peng, Yin, Hui-Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9575818/
https://www.ncbi.nlm.nih.gov/pubmed/36254054
http://dx.doi.org/10.1097/MD.0000000000030739
_version_ 1784811395063218176
author Zhang, Miao
Sun, Ming-Yue
Chen, Qi-Ting
Xu, Feng-Qin
Chen, Zong-Zheng
Wei, Wen-Bo
Wang, Rui-Ting
Xu, Gui-Peng
Yin, Hui-Jun
author_facet Zhang, Miao
Sun, Ming-Yue
Chen, Qi-Ting
Xu, Feng-Qin
Chen, Zong-Zheng
Wei, Wen-Bo
Wang, Rui-Ting
Xu, Gui-Peng
Yin, Hui-Jun
author_sort Zhang, Miao
collection PubMed
description Percutaneous coronary intervention (PCI), the most common method in treating coronary artery disease (CAD), has a variety of side effects. Yiqi Huoxue therapy (YQHX) can effectively alleviate the symptoms of patients and reduce the side effects. However, a reliable and systematic assessment of the methodologies is not available. METHODS: Seven electronic databases were searched to identify randomized controlled trials of YQHX method for CAD after PCI. The quality assessment of the trials included was performed by employing the Cochrane Risk of Bias tool. RESULTS: One thousand eight hundred sixty-eight patients from 23 randomized controlled trials were included in this review. The aggregated results showed that the experimental group got better effect in increasing ORR, TCMSRR, ECG, HDL-C, and in lowering the level of CRP, TC, and MACE in comparison with the control group. CONCLUSION: YQHX method is a valid complementary and alternative therapy in the management of CAD after PCI, and is an effective and safe therapy for CAD.
format Online
Article
Text
id pubmed-9575818
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-95758182022-10-17 The efficacy of Yiqi Huoxue method in treating coronary artery disease after percutaneous coronary intervention: A meta-analysis in accordance with PRISMA guideline Zhang, Miao Sun, Ming-Yue Chen, Qi-Ting Xu, Feng-Qin Chen, Zong-Zheng Wei, Wen-Bo Wang, Rui-Ting Xu, Gui-Peng Yin, Hui-Jun Medicine (Baltimore) Research Article Percutaneous coronary intervention (PCI), the most common method in treating coronary artery disease (CAD), has a variety of side effects. Yiqi Huoxue therapy (YQHX) can effectively alleviate the symptoms of patients and reduce the side effects. However, a reliable and systematic assessment of the methodologies is not available. METHODS: Seven electronic databases were searched to identify randomized controlled trials of YQHX method for CAD after PCI. The quality assessment of the trials included was performed by employing the Cochrane Risk of Bias tool. RESULTS: One thousand eight hundred sixty-eight patients from 23 randomized controlled trials were included in this review. The aggregated results showed that the experimental group got better effect in increasing ORR, TCMSRR, ECG, HDL-C, and in lowering the level of CRP, TC, and MACE in comparison with the control group. CONCLUSION: YQHX method is a valid complementary and alternative therapy in the management of CAD after PCI, and is an effective and safe therapy for CAD. Lippincott Williams & Wilkins 2022-10-14 /pmc/articles/PMC9575818/ /pubmed/36254054 http://dx.doi.org/10.1097/MD.0000000000030739 Text en Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY) (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Zhang, Miao
Sun, Ming-Yue
Chen, Qi-Ting
Xu, Feng-Qin
Chen, Zong-Zheng
Wei, Wen-Bo
Wang, Rui-Ting
Xu, Gui-Peng
Yin, Hui-Jun
The efficacy of Yiqi Huoxue method in treating coronary artery disease after percutaneous coronary intervention: A meta-analysis in accordance with PRISMA guideline
title The efficacy of Yiqi Huoxue method in treating coronary artery disease after percutaneous coronary intervention: A meta-analysis in accordance with PRISMA guideline
title_full The efficacy of Yiqi Huoxue method in treating coronary artery disease after percutaneous coronary intervention: A meta-analysis in accordance with PRISMA guideline
title_fullStr The efficacy of Yiqi Huoxue method in treating coronary artery disease after percutaneous coronary intervention: A meta-analysis in accordance with PRISMA guideline
title_full_unstemmed The efficacy of Yiqi Huoxue method in treating coronary artery disease after percutaneous coronary intervention: A meta-analysis in accordance with PRISMA guideline
title_short The efficacy of Yiqi Huoxue method in treating coronary artery disease after percutaneous coronary intervention: A meta-analysis in accordance with PRISMA guideline
title_sort efficacy of yiqi huoxue method in treating coronary artery disease after percutaneous coronary intervention: a meta-analysis in accordance with prisma guideline
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9575818/
https://www.ncbi.nlm.nih.gov/pubmed/36254054
http://dx.doi.org/10.1097/MD.0000000000030739
work_keys_str_mv AT zhangmiao theefficacyofyiqihuoxuemethodintreatingcoronaryarterydiseaseafterpercutaneouscoronaryinterventionametaanalysisinaccordancewithprismaguideline
AT sunmingyue theefficacyofyiqihuoxuemethodintreatingcoronaryarterydiseaseafterpercutaneouscoronaryinterventionametaanalysisinaccordancewithprismaguideline
AT chenqiting theefficacyofyiqihuoxuemethodintreatingcoronaryarterydiseaseafterpercutaneouscoronaryinterventionametaanalysisinaccordancewithprismaguideline
AT xufengqin theefficacyofyiqihuoxuemethodintreatingcoronaryarterydiseaseafterpercutaneouscoronaryinterventionametaanalysisinaccordancewithprismaguideline
AT chenzongzheng theefficacyofyiqihuoxuemethodintreatingcoronaryarterydiseaseafterpercutaneouscoronaryinterventionametaanalysisinaccordancewithprismaguideline
AT weiwenbo theefficacyofyiqihuoxuemethodintreatingcoronaryarterydiseaseafterpercutaneouscoronaryinterventionametaanalysisinaccordancewithprismaguideline
AT wangruiting theefficacyofyiqihuoxuemethodintreatingcoronaryarterydiseaseafterpercutaneouscoronaryinterventionametaanalysisinaccordancewithprismaguideline
AT xuguipeng theefficacyofyiqihuoxuemethodintreatingcoronaryarterydiseaseafterpercutaneouscoronaryinterventionametaanalysisinaccordancewithprismaguideline
AT yinhuijun theefficacyofyiqihuoxuemethodintreatingcoronaryarterydiseaseafterpercutaneouscoronaryinterventionametaanalysisinaccordancewithprismaguideline
AT zhangmiao efficacyofyiqihuoxuemethodintreatingcoronaryarterydiseaseafterpercutaneouscoronaryinterventionametaanalysisinaccordancewithprismaguideline
AT sunmingyue efficacyofyiqihuoxuemethodintreatingcoronaryarterydiseaseafterpercutaneouscoronaryinterventionametaanalysisinaccordancewithprismaguideline
AT chenqiting efficacyofyiqihuoxuemethodintreatingcoronaryarterydiseaseafterpercutaneouscoronaryinterventionametaanalysisinaccordancewithprismaguideline
AT xufengqin efficacyofyiqihuoxuemethodintreatingcoronaryarterydiseaseafterpercutaneouscoronaryinterventionametaanalysisinaccordancewithprismaguideline
AT chenzongzheng efficacyofyiqihuoxuemethodintreatingcoronaryarterydiseaseafterpercutaneouscoronaryinterventionametaanalysisinaccordancewithprismaguideline
AT weiwenbo efficacyofyiqihuoxuemethodintreatingcoronaryarterydiseaseafterpercutaneouscoronaryinterventionametaanalysisinaccordancewithprismaguideline
AT wangruiting efficacyofyiqihuoxuemethodintreatingcoronaryarterydiseaseafterpercutaneouscoronaryinterventionametaanalysisinaccordancewithprismaguideline
AT xuguipeng efficacyofyiqihuoxuemethodintreatingcoronaryarterydiseaseafterpercutaneouscoronaryinterventionametaanalysisinaccordancewithprismaguideline
AT yinhuijun efficacyofyiqihuoxuemethodintreatingcoronaryarterydiseaseafterpercutaneouscoronaryinterventionametaanalysisinaccordancewithprismaguideline